Xanadu Bio Obtains Licenses and Options to Novel Platform Technologies from Yale University to Develop an Intranasal SARS CoV-2 mRNA Vaccine Booster Aimed at Inducing Local Mucosal Immunity to Prevent SARS CoV-2 Infection and Virus Transmission
February 08, 2022 07:30 ET
|
Xanadu Bio
~ Company licenses PACE, a next generation polymeric nanoparticle delivery platform, and options intranasal PACE/Spike mRNA and Spike recombinant protein vaccine boosters for the treatment of...
Study: New Intervention Helps with Alcohol-related Cognitive Impairment
December 14, 2020 08:00 ET
|
Posit Science
SAN FRANCISCO, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Researchers at Yale published positive results from a pilot study of a novel combination therapy in patients with Mild Cognitive Impairment related...
Cybrexa Therapeutics Expands Scientific Advisory Board With Appointment of Leader in Lung Cancer Research Roy Herbst, M.D., Ph.D.
August 03, 2020 07:00 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ tumor targeting...
Cybrexa Therapeutics to Present First Efficacy and Safety Data From Its Lead Program CBX-12 and Initial Data From CBX-13 at the American Association for Cancer Research (AACR) Virtual Annual Meeting II
May 15, 2020 04:00 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., May 15, 2020 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ tumor targeting...
Cybrexa Therapeutics Announces Expansion of Its Anticancer Pipeline
December 09, 2019 08:30 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, today...
ReNetX Bio Announces Initiation of Patient Dosing in the First Phase 1 Clinical Trial of Fusion Protein AXER-204
August 14, 2019 09:02 ET
|
ReNetx Bio
NEW HAVEN, Conn., Aug. 14, 2019 (GLOBE NEWSWIRE) -- ReNetX Bio, Inc., a leading biotechnology company committed to reversing disease and damage for patients suffering from central nervous system...
Rise in Medical Cannabis Research Spurs Demand For Precise Measurement Tools
June 05, 2019 09:00 ET
|
Gofire, Inc.
DENVER, June 05, 2019 (GLOBE NEWSWIRE) -- Healthcare technology firm Gofire™, an innovator of hardware and software solutions that aid in dose delivery, health tracking, and medication management,...
Ossa Fisher Named Istation’s President
January 08, 2019 10:28 ET
|
Istation Inc.
Dallas, TX, Jan. 08, 2019 (GLOBE NEWSWIRE) -- Ossa Fisher is the new president of Istation, a Dallas-based education technology company providing computer-adaptive assessments and instruction in...
Farooq Kathwari Honored With Yale Chief Executive Leadership Institute's Lifetime of Leadership Award
June 21, 2018 14:01 ET
|
Ethan Allen
DANBURY, Conn., June 21, 2018 (GLOBE NEWSWIRE) -- Ethan Allen chairman, president and CEO Farooq Kathwari accepted the Yale Chief Executive Leadership Institute's (CELI) Lifetime of Leadership Award...
Remedy Pharmaceuticals Co-founder and CEO Brings Clinical Trial and Company-Building Experience to ReNetX Bio Advisory Board
February 12, 2018 10:00 ET
|
ReNetX Bio
NEW HAVEN, Conn., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Sven Jacobson will be the first to admit that developing a new therapeutic for spinal cord injury is a challenging road. But the latest member of...